Kulkarni Hrishikesh S, Belperio John A, Atkinson Carl
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA.
Department of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
J Clin Invest. 2025 Oct 1;135(19). doi: 10.1172/JCI188346.
The complement system is an evolutionarily conserved host defense system that has evolved from invertebrates to mammals. Over time, this system has become increasingly appreciated as having effects beyond purely bacterial clearance, with clinically relevant implications in transplantation, particularly lung transplantation. For many years, complement activation in lung transplantation was largely focused on antibody-mediated injuries. However, recent studies have highlighted the importance of both canonical and noncanonical complement activation in shaping adaptive immune responses, which influence alloimmunity. These studies, together with the emergence of FDA-approved complement therapeutics and other drugs in the pipeline that function at different points of the cascade, have led to an increased interest in regulating the complement system to improve donor organ availability as well as improving both short- and long-term outcomes after lung transplantation. In this Review, we provide an overview of the when, what, and how of complement in lung transplantation, posing the questions of: when does complement activation occur, what components of the complement system are activated, and how can this activation be controlled? We conclude that complement activation occurs at multiple stages of the transplant process and that randomized controlled trials will be necessary to realize the therapeutic potential of neutralizing this activation to improve outcomes after lung transplantation.
补体系统是一种从无脊椎动物进化到哺乳动物的进化上保守的宿主防御系统。随着时间的推移,人们越来越认识到该系统的作用不仅限于单纯的细菌清除,在移植尤其是肺移植方面具有临床相关意义。多年来,肺移植中的补体激活主要集中在抗体介导的损伤上。然而,最近的研究强调了经典和非经典补体激活在塑造适应性免疫反应中的重要性,而适应性免疫反应会影响同种免疫。这些研究,再加上美国食品药品监督管理局(FDA)批准的补体疗法以及正在研发的在补体级联反应不同点起作用的其他药物的出现,使得人们对调节补体系统以提高供体器官可用性以及改善肺移植后的短期和长期结果的兴趣增加。在本综述中,我们概述了肺移植中补体激活的时间、激活的成分以及如何控制这种激活,提出了以下问题:补体激活何时发生,补体系统的哪些成分被激活,以及如何控制这种激活?我们得出结论,补体激活发生在移植过程的多个阶段,需要进行随机对照试验以实现中和这种激活以改善肺移植后结果的治疗潜力。